SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

ASP3026

Item No. 18491



CAS Registry No.: 1097917-15-1
Formal Name: N^2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)1-piperidinyl]phenyl]-N^4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine
MF: $C_{29}H_{40}N_8O_3S$
FW: 580.7
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 206, 268, 303 nm

Laboratory Procedures

For long term storage, we suggest that ASP3026 be stored as supplied at -20°C. It should be stable for at least two years.

ASP3026 is supplied as a crystalline solid. A stock solution may be made by dissolving the ASP3026 in the solvent of choice. ASP3026 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ASP3026 in ethanol is approximately 0.5 mg/ml and approximately 2 mg/ml in DMSO and DMF.

ASP3026 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ASP3026 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ASP3026 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

ASP3026 is an ATP-competitive, second-generation ALK inhibitor (IC_{50} = 3.5 nM) that also inhibits ROS (IC_{50} = 8.9 nM) and ACK (IC_{50} = 5.8 nM).[1,2] It inhibits neuroblastoma-activating ALK mutants F1174L (IC_{50} = 10 nM) and R1275Q (IC_{50} = 5.4 nM) and demonstrates antitumor activity in xenograft mouse models.[1,2] ASP3026 has been shown to overcome crizotinib (Item No. 12087) resistance in non-small cell lung cancer, and is currently being evaluated in clinical trials of patients with ALK-positive solid tumors.[2]

References

1. Mori, M., Ueno, Y., Konagai, S., *et al.* The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. *Mol. Cancer Ther.* **13(2)**, 329-340 (2015).
2. Awad, M.M. and Shaw, A.T. ALK inhibitors in non-small cell lung cancer: Crizotinib and beyond. *Clin. Adv. Hematol. Oncol.* **12(7)**, 429-439 (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM